ClinicalTrials.gg
CompletedNCT04276064Updated Mar 4, 2024

Modulation of Sleep Perception Through Auditory Closed-loop Stimulation of Brain Oscillatory Activity

An interventional study of Auditory closed-loop stimulation: slow oscillation boosting and Auditory closed-loop stimulation: slow oscillation disruption in Sleep and Insomnia, sponsored by Christoph Nissen. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Christoph Nissen · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Sleep Initiation and Maintenance Disorders with a site in Switzerland — 8 open to participants now, 9 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Switzerland.

Enrollment
15th of 27
60 · median 68
Started
2021
with 4 others
No phase
15 of 34
4 open now
Registered
17th of 34
by date
Lead sponsor
2 of 34
Christoph Nissen

Among the 34 studies in Sleep Initiation and Maintenance Disorders with a site in Switzerland, this one is the 15th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2021, is one of 15 with no phase, and was the 17th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

8 of the 34 studies in Sleep Initiation and Maintenance Disorders with a site in Switzerland are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Sleep Initiation and Maintenance Disorders with a site in Switzerland, or all of them as a file.
02

Study summary

Sleep is ubiquitous in animals and humans, and disruptions are of high clinical importance. Still, the neural basis of sleep perception is insufficiently understood, which limits the development of new treatments. The current project is designed to further contribute to the understanding of the neural basis of sleep perception and to the development of innovative treatments for disrupted sleep (insomnia).

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For patients: diagnosis of ID according to DSM 5 criteria; for controls: mentally and somatically healthy
  • Age 18 to 65 years
  • Written

Exclusion criteria

Exclusion Criteria:

  • Relevant current or past serious medical disorder, including but not limited to cardiac arrhythmia, diabetes mellitus, and chronic pain conditions.
  • Neurological conditions including epilepsy, history of brain injury, encephalitis or any organic brain syndrome
  • Current or past mental disorders (life time prevalence), e.g. depressive disorder, attention deficit disorder, psychotic disorders, anxiety disorder, posttraumatic stress disorder
  • Sleep disorders (except ID for patients), including movement-related sleep disorders (PLMS index with arousal > 5) or breathing-related sleep disorders (AHI > 15)
  • Intake of CNS active medication (except appropriate thyroid hormone substitution)
  • Current or past substance abuse or dependency
  • Smoking > 5 cigarettes per day
  • Excessive caffeine consumption (> 500 mg or 5 cups coffee per day)
  • Irregular sleep schedules resulting from shift work, travelling or personal habits, defined as a sleep/wake time deviation > 4 hours in the weekly routine or as a habitual total sleep time \< 4.5 hours or > 10 hours per night
  • Known pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Patients with insomnia

    Patients with insomnia disorder according to DSM-5 criteria

    Device: Auditory closed-loop stimulation: slow oscillation boosting · Device: Auditory closed-loop stimulation: slow oscillation disruption · Device: Sham stimulation

  • Experimental
    Healthy controls

    Healthy controls

    Device: Auditory closed-loop stimulation: slow oscillation boosting · Device: Auditory closed-loop stimulation: slow oscillation disruption · Device: Sham stimulation

Interventions

  • DeviceAuditory closed-loop stimulation: slow oscillation boosting

    Auditory-closed loop stimulation: slow oscillation boosting

  • DeviceAuditory closed-loop stimulation: slow oscillation disruption

    Auditory closed-loop stimulation: slow oscillation disruption

  • DeviceSham stimulation

    Sham stimulation

06

What researchers measure

Primary outcomes

  1. Modulation Index

    Measure of phase-amplitude coupling

    Time frame: Averaged across NREM sleep of the baseline night (about 6 hours)

07

Study locations

1 site
  • University of Bern
    Bern, Switzerland
08

References and documents

Publications

  • Mikutta C, Feige B, Maier JG, Hertenstein E, Holz J, Riemann D, Nissen C. Phase-amplitude coupling of sleep slow oscillatory and spindle activity correlates with overnight memory consolidation. J Sleep Res. 2019 Dec;28(6):e12835. doi: 10.1111/jsr.12835. Epub 2019 Mar 7. PubMed 30848042 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Feb 2024, 27 months.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's 27 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2020
First posted
Feb 19, 2020
StartActual
Nov 1, 2021
Primary completionActual
Feb 14, 2024
CompletionActual
Feb 14, 2024
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04276064
Lead sponsor
Christoph Nissen
Responsible party
Christoph Nissen (Chief physician, University of Bern) — Sponsor-investigator
First posted
Feb 19, 2020
Start date
Nov 1, 2021
Primary completion
Feb 14, 2024
Completion
Feb 14, 2024
Last update
Mar 4, 2024

Study contacts

Christoph Nissen, MD
principal investigator · University of Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion